These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15355907)
1. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907 [TBL] [Abstract][Full Text] [Related]
2. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351 [TBL] [Abstract][Full Text] [Related]
3. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470 [TBL] [Abstract][Full Text] [Related]
5. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701 [TBL] [Abstract][Full Text] [Related]
6. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Janssen JW; Cuny M; Orsetti B; Rodriguez C; Vallés H; Bartram CR; Schuuring E; Theillet C Int J Cancer; 2002 Dec; 102(6):608-14. PubMed ID: 12448002 [TBL] [Abstract][Full Text] [Related]
8. Functional characterization of EMSY gene amplification in human cancers. Wilkerson PM; Dedes KJ; Wetterskog D; Mackay A; Lambros MB; Mansour M; Frankum J; Lord CJ; Natrajan R; Ashworth A; Reis-Filho JS J Pathol; 2011 Sep; 225(1):29-42. PubMed ID: 21735447 [TBL] [Abstract][Full Text] [Related]
9. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623 [TBL] [Abstract][Full Text] [Related]
10. The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis. Baykara O; Dalay N; Bakir B; Bulut P; Kaynak K; Buyru N Int J Med Sci; 2017; 14(7):675-679. PubMed ID: 28824300 [No Abstract] [Full Text] [Related]
11. Genetic alterations of CCND1 and EMSY in breast cancers. Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977 [TBL] [Abstract][Full Text] [Related]
12. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations. Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328 [TBL] [Abstract][Full Text] [Related]
13. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566 [TBL] [Abstract][Full Text] [Related]
14. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415 [TBL] [Abstract][Full Text] [Related]
15. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818 [TBL] [Abstract][Full Text] [Related]
16. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Egawa C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S Int J Cancer; 2002 Apr; 98(6):879-82. PubMed ID: 11948466 [TBL] [Abstract][Full Text] [Related]
17. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Cousineau I; Belmaaza A Mol Genet Genomics; 2011 Apr; 285(4):325-40. PubMed ID: 21409565 [TBL] [Abstract][Full Text] [Related]
18. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Madjd Z; Akbari ME; Zarnani AH; Khayamzadeh M; Kalantari E; Mojtabavi N Asian Pac J Cancer Prev; 2014; 15(4):1783-9. PubMed ID: 24641409 [TBL] [Abstract][Full Text] [Related]
19. Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. Raouf A; Brown L; Vrcelj N; To K; Kwok W; Huntsman D; Eaves CJ J Natl Cancer Inst; 2005 Sep; 97(17):1302-6. PubMed ID: 16145051 [TBL] [Abstract][Full Text] [Related]
20. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]